

Patient Alert Card



Welireg® 40 mg film-coated tablets
(belzutifan)

Important Safety Information

Please keep this card with you at all times

- This patient alert card contains important safety information that you need to be aware of before, during, and after treatment with WELIREG (belzutifan).
- Show this card to any health care professional involved in your care.
- If you get any side effects, talk to your doctor, pharmacist or nurse.

This includes any possible side effects not listed in the package leaflet.

Side effects can be reported to the Ministry of Health by using the link:

<https://sideeffects.health.gov.il>

Side effects can also be reported directly to MSD company on Tel: 09-9533333.

By reporting side effects, you can help provide more information on the safety of this medicine.

Important Safety Information for Patients

Welireg can cause low oxygen levels in your body that can be severe and may require you to stop treatment, receive oxygen therapy, or be hospitalized. This is called 'hypoxia'.

Your healthcare provider will monitor your oxygen levels before you start and during treatment with Welireg.

Contact your doctor immediately if you experience any of the following:

- Difficulty breathing or shortness of breath
- Increased heart rate
- Rapid breathing
- Feeling anxious or restless
- Bluish discoloration of the skin and around your mouth
- You are unable to complete sentences when at rest due to breathlessness
- Unusual tiredness
- Confusion

If these signs or symptoms become severe or are rapidly worsening, then go to your nearest emergency room or call 101 immediately to seek medical advice.

Important Contact Information

Name of physician

Patient name

Patient phone

Physician / clinic phone number

Physician after-hours phone number

Emergency contact (name)

Emergency contact (phone number)

Important Information for Healthcare Providers

Please note that this patient is receiving treatment with Welireg (belzutifan). Welireg may increase the risk of hypoxia. Please refer to the product information regarding the management of hypoxia.

For additional information, you can contact MSD company on Tel: 09-9533333.



Please refer to the patient information leaflet
Inside the product package before use

Welireg's patient safety information card is based on the card distributed in GB

August 2022.WEL-PAC-001